(NASDAQ: SUPN) Supernus Pharmaceuticals's forecast annual revenue growth rate of 14.48% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.47%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.64%.
Supernus Pharmaceuticals's revenue in 2025 is $681,539,000.On average, 8 Wall Street analysts forecast SUPN's revenue for 2025 to be $41,106,006,622, with the lowest SUPN revenue forecast at $38,896,721,466, and the highest SUPN revenue forecast at $42,746,485,425. On average, 8 Wall Street analysts forecast SUPN's revenue for 2026 to be $50,708,627,566, with the lowest SUPN revenue forecast at $46,308,405,847, and the highest SUPN revenue forecast at $54,336,488,241.
In 2027, SUPN is forecast to generate $58,256,779,600 in revenue, with the lowest revenue forecast at $52,062,409,620 and the highest revenue forecast at $65,481,537,700.